Concise review: Cell therapies for hereditary metabolic liver diseases - Concepts, clinical results, and future developments

Stem Cells

Volumn 33, Issue 4, 2015, Pages 1055-1062

  Cantz, Tobias ^a,b   Sharma, Amar Deep ^b   Ott, Michael ^b,c  

^a Excellence Cluster REBIRTH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Cellular therapy; Clinical translation; Hepatic stem cells; Hepatocyte differentiation; Liver; Pluripotent stem cells; Progenitor cells

Indexed keywords

CELL THERAPY; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; ENGRAFTMENT; FUTUROLOGY; HEPATOCYTE TRANSPLANTATION; HEREDITARY METABOLIC LIVER DISEASE; HUMAN; INBORN ERROR OF METABOLISM; LIVER CELL; LIVER DISEASE; LIVER PARENCHYMA; LIVER REGENERATION; LIVER TRANSPLANTATION; NONHUMAN; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; FORECASTING; LIVER DISEASES; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION; TRENDS;

ANIMALIA;

ANIMALS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; FORECASTING; HEPATOCYTES; HUMANS; LIVER DISEASES; LIVER REGENERATION; STEM CELL TRANSPLANTATION;

EID: 84925654851     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1920     Document Type: Review

References (91)

1. Sigal SH, Brill S, Fiorino AS, et al. The liver as a stem cell and lineage system. Am J Physiol 1992; 263: G139-G148.
2. Lanzoni G, Oikawa T, Wang Y, et al. Concise review: Clinical programs of stem cell therapies for liver and pancreas. Stem Cells 2013; 31: 2047-2060.
3. Cardinale V, Wang Y, Carpino G, et al. The biliary tree-A reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol 2012; 9: 231-240.
4. Cardinale V, Wang Y, Carpino G, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 2011; 54: 2159-2172.
5. Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet 2011; 43: 34-41.
6. Sackett SD, Li Z, Hurtt R, et al. Foxl1 is a marker of bipotential hepatic progenitor cells in mice. Hepatology 2009; 49: 920-929.
7. Shin S, Walton G, Aoki R, et al. Foxl1-Cre-marked adult hepatic progenitors have clonogenic and bilineage differentiation potential. Genes Dev 2011; 25: 1185-1192.
8. Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by wnt-driven regeneration. Nature 2013; 494: 247-250.
9. Yimlamai D, Christodoulou C, Galli GG, et al. Hippo pathway activity influences liver cell fate. Cell 2014; 157: 1324-1338.
10. Tarlow BD, Pelz C, Naugler WE, et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 2014; 15: 605-618.
11. Kang LI, Mars WM, Michalopoulos GK., Signals and cells involved in regulating liver regeneration. Cells 2012; 1: 1261-1292.
12. Quante M, Wang TC., Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2009; 6: 724-737.
13. Duncan AW, Dorrell C, Grompe M., Stem cells and liver regeneration. Gastroenterology 2009; 137: 466-481.
14. Grisham JW, Hartroft WS., Morphologic identification by electron microscopy of "oval" cells in experimental hepatic degeneration. Lab Invest 1961; 10: 317-332.
15. Suzuki A, Zheng YW, Kaneko S, et al. Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver. J Cell Biol 2002; 156: 173-184.
16. Fausto N., Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells. Hepatology 2004; 39: 1477-1487.
17. Malato Y, Naqvi S, Schurmann N, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 2011; 121: 4850-4860.
18. Schaub JR, Malato Y, Gormond C, et al. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Rep 2014; 8: 933-939.
19. Yanger K, Knigin D, Zong Y, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell Stem Cell 2014; 15: 340-349.
20. Tarlow BD, Finegold MJ, Grompe M., Clonal tracing of Sox9+ liver progenitors in mouse oval cell injury. Hepatology 2014; 60: 278-289.
21. Kusano M, Mito M. A study of hepatocellular transplantation. Nihon Rinsho 1992;50:1679-1688.
22. Komori J, Boone L, DeWard A, et al. The mouse lymph node as an ectopic transplantation site for multiple tissues. Nat Biotechnol 2012; 30: 976-983.
23. Joshi M, B Patil P, He Z, et al. Fetal liver-derived mesenchymal stromal cells augment engraftment of transplanted hepatocytes. Cytotherapy 2012; 14: 657-669.
24. Touboul T, Hannan NR, Corbineau S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010; 51: 1754-1765.
25. Sgodda M, Mobus S, Hoepfner J, et al. Improved hepatic differentiation strategies for human induced pluripotent stem cells. Curr Mol Med 2013; 13: 842-855.
26. Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013; 499: 481-484.
27. Gupta S, Rajvanshi P, Sokhi R, et al. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 1999; 29: 509-519.
28. Oertel M, Menthena A, Chen YQ, et al. Comparison of hepatic properties and transplantation of Thy-1(+) and Thy-1(-) cells isolated from embryonic day 14 rat fetal liver. Hepatology 2007; 46: 1236-1245.
29. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204: 1973-1987.
30. Woo DH, Kim SK, Lim HJ, et al. Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice. Gastroenterology 2012; 142: 602-611.
31. Haridass D, Yuan Q, Becker PD, et al. Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. Am J Pathol 2009; 175: 1483-1492.
32. Najimi M, Khuu DN, Lysy PA, et al. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007; 16: 717-728.
33. Fisher RA, Strom SC., Human hepatocyte transplantation: Worldwide results. Transplantation 2006; 82: 441-449.
34. Fitzpatrick E, Mitry RR, Dhawan A., Human hepatocyte transplantation: State of the art. J Intern Med 2009; 266: 339-357.
35. Dhawan A, Mitry RR, Hughes RD., Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29: 431-435.
36. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-1426.
37. Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005; 14: 151-157.
38. Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359: 317-318.
39. Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: Technique, safety, and metabolic follow-up. Transplantation 2003; 76: 735-738.
40. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-1814.
41. Stephenne X, Najimi M, Sibille C, et al. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006; 130: 1317-1323.
42. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111: 1262-1267.
43. Mitry RR, Dhawan A, Hughes RD, et al. One liver, three recipients: Segment IV from split-liver procedures as a source of hepatocytes for cell transplantation. Transplantation 2004; 77: 1614-1616.
44. Stephenne X, Najimi M, Smets F, et al. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5: 2058-2061.
45. Meyburg J, Das AM, Hoerster F, et al. One liver for four children: First clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009; 87: 636-641.
46. Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation-A novel treatment for ornithine transcarbamylase deficiency. Am J Transplant 2008; 8: 452-457.
47. Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63: 559-569.
48. Smets FN, Stephenne X, Debray G, et al. Hepatocyte transplantation transforms severe phenylketonuria to mild hyperphenylalaninemia. Gastroenterology 2011; 140: S967.
49. Lee KW, Lee JH, Shin SW, et al. Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant 2007; 16: 629-637.
50. Lysy PA, Najimi M, Stephenne X, et al. Liver cell transplantation for Crigler-Najjar syndrome type I: Update and perspectives. World J Gastroenterol 2008; 14: 3464-3470.
51. Allen KJ, Mifsud NA, Williamson R, et al. Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transplant 2008; 14: 688-694.
52. Dhawan A, Puppi J, Hughes RD, et al. Human hepatocyte transplantation: Current experience and future challenges. Nat Rev Gastroenterol Hepatol 2010; 7: 288-298.
53. Alexandrova K, Griesel C, Barthold M, et al. Large-scale isolation of human hepatocytes for therapeutic application. Cell Transplant 2005; 14: 845-853.
54. Yudkoff M, Daikhin Y, Nissim I, et al. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest 1996; 98: 2167-2173.
55. Tuchman M, Caldovic L, Daikhin Y, et al. N-Carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res 2008; 64: 213-217.
56. Ah Mew N, McCarter R, Daikhin Y, et al. N-Carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics 2010; 126: e208-e214.
57. Berardis S, Lombard C, Evraerts J, et al. Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS one 2014; 9: e86137.
58. Sokal EM, Stephenne X, Ottolenghi C, et al. Liver engraftment and repopulation by in vitro expanded adult derived human liver stem cells in a child with ornithine carbamoyltransferase deficiency. JIMD Rep 2014; 13: 65-72.
59. Dobbelaere D, Semts F, McKiernam P, et al. Phase I/II multicenter trial of liver derived mesenchymal stem cells (hepastemr) for the treatment of urea cycle disorder and Crigler Najjar syndrome. Interim analysis at 6 months post infusion: Society for the Study of Inborn Errors of Metabolism (SSIEM)-Annual Symposium. Vol 37. Innsbruck: J Inherit Metab Dis 2014: S34.
60. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, et al. Deriving functional hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol 2014; 30: 1G 5 1-1G 5 12.
61. Hannan NR, Segeritz CP, Touboul T, et al. Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 2013; 8: 430-437.
62. Möbus S, Yang D, Yuan Q, et al. Microrna-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells. J Hepatol 2015; 62: 101-110.
63. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of [Agr]1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478: 391-394.
64. Eggenschwiler R, Loya K, Wu G, et al. Sustained knockdown of a disease-causing gene in patient specific induced pluripotent stem cells using lentiviral vector based gene therapy. Stem Cells Translat Med 2013; 2: 641-654.
65. Choi SM, Kim Y, Shim JS, et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013; 57: 2458-2468.
66. Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120: 3127-3136.
67. Fattahi F, Asgari S, Pournasr B, et al. Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells. Mol Biotechnol 2013; 54: 863-873.
68. Ordonez MP, Goldstein LS., Using human-induced pluripotent stem cells to model monogenic metabolic disorders of the liver. Semin Liver Dis 2012; 32: 298-306.
69. Wu G, Liu N, Rittelmeyer I, et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol 2011; 9: e1001099.
70. Tiemann U, Sgodda M, Warlich E, et al. Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytometry A 2011; 79A: 426-435.
71. Carey BW, Markoulaki S, Hanna JH, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011; 9: 588-598.
72. Warlich E, Kühle J, Cantz T, et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 2011; 19: 782-789.
73. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B: Phys Biol Sci 2009; 85: 348-362.
74. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
75. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
76. Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341: 651-654.
77. Zhu S, Rezvani M, Harbell J, et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014; 508: 93-97.
78. Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389.
79. Huang P, Zhang L, Gao Y, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 2014; 14: 370-384.
80. Sekiya S, Suzuki A., Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475: 390-393.
81. Du Y, Wang J, Jia J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 2014; 14: 394-403.
82. Cahan P, Li H, Morris SA, et al. Cellnet: Network biology applied to stem cell engineering. Cell 2014; 158: 903-915.
83. Morris SA, Cahan P, Li H, et al. Dissecting engineered cell types and enhancing cell fate conversion via Cellnet. Cell 2014; 158: 889-902.
84. Pfaff N, Cantz T., From skin to blood: A new member joins the iClub. Cell Stem Cell 2013; 13: 131-133.
85. Slehria S, Rajvanshi P, Ito Y, et al. Hepatic sinusoidal vasodilators improve transplanted cell engraftment and ameliorate microcirculatory perturbations in the liver. Hepatology 2002; 35: 1320-1328.
86. Bahde R, Kapoor S, Bandi S, et al. Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver. Hepatology 2013; 57: 320-330.
87. Bahde R, Kapoor S, Viswanathan P, et al. Endothelin-1 receptor a blocker darusentan decreases hepatic changes and improves liver repopulation after cell transplantation in rats. Hepatology 2014; 59: 1107-1117.
88. Koenig S, Yuan Q, Krause P, et al. Regional transient portal ischemia and irradiation as preparative regimen for hepatocyte transplantation. Cell Transplant 2011; 20: 303-311.
89. Yannam GR, Han B, Setoyama K, et al. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. Int J Radiat Oncol Biol Phys 2014; 88: 404-411.
90. Puppi J, Strom SC, Hughes RD, et al. Improving the techniques for human hepatocyte transplantation: Report from a consensus meeting in London. Cell Transplant 2012; 21: 1-10.
91. Soto-Gutierrez A, Zhang L, Medberry C, et al. A whole-organ regenerative medicine approach for liver replacement. Tissue Eng Part C: Methods 2011; 17: 677-686.